CD8A and melanoma: It has been recently demonstrated that EGCG inhibits IFN-γ-induced PD-L1 and PD-L2 expression, and JAK-STAT signaling in melanoma cells, while in animal studies EGCG blocked PD-L1 expression, leading to the activation of CD8+ T cells [176].